Literature DB >> 22071692

Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation.

Jae-Seok Roe1, Hwa-Ryeon Kim, In-Young Hwang, Nam-Chul Ha, Seong-Tae Kim, Eun-Jung Cho, Hong-Duk Youn.   

Abstract

von-Hippel Lindau protein (pVHL) suppresses tumorigenesis in the kidney, in part through regulation of hypoxia-inducible factor alpha (HIF alpha). However, HIF has been proposed to be necessary but insufficient for renal tumorigenesis. p53 was implicated as a transcription factor that is regulated by pVHL, but the molecular mechanism by which pVHL regulates p53 on DNA damage is unknown. We demonstrated that checkpoint kinase-2 (Chk2) binds to the beta-domain of pVHL and phosphorylates Ser 111 on DNA damage. Notably, this modification enhances pVHL-mediated transactivation of p53 by recruiting p300 and Tip60 to the chromatin of p53 target gene. Further, the naturally occurring pVHL mutants pVHL-S111R and pVHL-S111C showed diminished binding to coactivators, ultimately retarding p53-mediated growth arrest and apoptosis. In this study, we determined the molecular mechanism by which pVHL transactivates p53 on DNA damage and demonstrated that p53-related pVHL subtype mutants regulate tumorigenecity in VHL diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22071692     DOI: 10.4161/cc.10.22.18096

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  16 in total

1.  pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases.

Authors:  In-Young Hwang; Jae-Seok Roe; Ja-Hwan Seol; Hwa-Ryeon Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Mol Cells       Date:  2012-02       Impact factor: 5.034

2.  Nek1 phosphorylates Von Hippel-Lindau tumor suppressor to promote its proteasomal degradation and ciliary destabilization.

Authors:  Mallikarjun Patil; Navjotsingh Pabla; Shuang Huang; Zheng Dong
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

3.  ROS-mediated activation of AKT induces apoptosis via pVHL in prostate cancer cells.

Authors:  Mahandranauth A Chetram; Danaya A Bethea; Valerie A Odero-Marah; Ayesha S Don-Salu-Hewage; Kia J Jones; Cimona V Hinton
Journal:  Mol Cell Biochem       Date:  2013-01-12       Impact factor: 3.396

4.  Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features.

Authors:  Timothy Ito; Jianming Pei; Essel Dulaimi; Craig Menges; Philip H Abbosh; Marc C Smaldone; David Y T Chen; Richard E Greenberg; Alexander Kutikov; Rosalia Viterbo; Robert G Uzzo; Joseph R Testa
Journal:  J Urol       Date:  2015-11-18       Impact factor: 7.450

5.  The "Sharp" blade against HIF-mediated metastasis.

Authors:  Ivano Amelio; Gerry Melino
Journal:  Cell Cycle       Date:  2012-11-27       Impact factor: 4.534

6.  The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2.

Authors:  P B Essers; T D Klasson; T C Pereboom; D A Mans; M Nicastro; K Boldt; R H Giles; A W MacInnes
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

Review 7.  Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.

Authors:  Eric Jonasch; Cheryl Lyn Walker; W Kimryn Rathmell
Journal:  Nat Rev Nephrol       Date:  2020-11-03       Impact factor: 28.314

Review 8.  Recent discoveries in the cycling, growing and aging of the p53 field.

Authors:  James A McCubrey; Zoya N Demidenko
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

9.  Phosphorylation and ubiquitination-dependent degradation of CABIN1 releases p53 for transactivation upon genotoxic stress.

Authors:  Soo-Youn Choi; Hyonchol Jang; Jae-Seok Roe; Seong-Tae Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Nucleic Acids Res       Date:  2013-01-08       Impact factor: 16.971

10.  Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.

Authors:  Carole Sourbier; Gaurav Srivastava; Manik C Ghosh; Sanchari Ghosh; Youfeng Yang; Gopal Gupta; William Degraff; Murali C Krishna; James B Mitchell; Tracey A Rouault; W Marston Linehan
Journal:  Oncotarget       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.